News and FDA Updates for Biomagnetics (OTC:BMGP), China Sky One (Nasdaq:CSKI), Covidien (NYSE:COV)
M.E. Garza
November 26, 2009
A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com
On 11/25/09, Biomagnetics Diagnostics Corp., (OTC:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, announced the Company will hold an investor conference call to discuss upcoming business opportunities and its agreement with one of the world´s premiere research laboratories.
On 11/25/09, China Sky One Medical, Inc. (Nasdaq:CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), announced the Company recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products ("ICPBP") examination for two of its new products: its Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) and its Determination Kit for Luteinizing Hormone (Colloidal Gold).
On 11/25/09, Covidien (NYSE:COV) will present at the 21st Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 2, 2009. Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will represent the Company in a session scheduled at 8:30 a.m. ET.
Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
Disclosure: No positions.
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
Certain sections of this report contain forward-looking statements that are based on our reporters´ expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company´s behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.